PL2818481T3 - Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi złośliwemu - Google Patents
Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi złośliwemuInfo
- Publication number
- PL2818481T3 PL2818481T3 PL13751159T PL13751159T PL2818481T3 PL 2818481 T3 PL2818481 T3 PL 2818481T3 PL 13751159 T PL13751159 T PL 13751159T PL 13751159 T PL13751159 T PL 13751159T PL 2818481 T3 PL2818481 T3 PL 2818481T3
- Authority
- PL
- Poland
- Prior art keywords
- cancer
- prevention
- treatment
- pharmaceutical composition
- pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012035342 | 2012-02-21 | ||
EP13751159.8A EP2818481B1 (en) | 2012-02-21 | 2013-02-21 | Pharmaceutical composition for treatment and/or prevention of cancer |
PCT/JP2013/054312 WO2013125630A1 (ja) | 2012-02-21 | 2013-02-21 | 癌の治療及び/又は予防用医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2818481T3 true PL2818481T3 (pl) | 2020-02-28 |
Family
ID=49005808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13751159T PL2818481T3 (pl) | 2012-02-21 | 2013-02-21 | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi złośliwemu |
Country Status (17)
Country | Link |
---|---|
US (1) | US9260513B2 (en:Method) |
EP (1) | EP2818481B1 (en:Method) |
JP (1) | JP6187257B2 (en:Method) |
KR (1) | KR102005308B1 (en:Method) |
CN (1) | CN104114581B (en:Method) |
AU (1) | AU2013223137B2 (en:Method) |
BR (1) | BR112014021099A2 (en:Method) |
CA (1) | CA2864999C (en:Method) |
DK (1) | DK2818481T3 (en:Method) |
ES (1) | ES2749672T3 (en:Method) |
HU (1) | HUE046788T2 (en:Method) |
IN (1) | IN2014KN01714A (en:Method) |
MX (1) | MX363136B (en:Method) |
PL (1) | PL2818481T3 (en:Method) |
PT (1) | PT2818481T (en:Method) |
RU (1) | RU2639522C2 (en:Method) |
WO (1) | WO2013125630A1 (en:Method) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160039295A (ko) | 2008-08-05 | 2016-04-08 | 도레이 카부시키가이샤 | 암의 검출 방법 |
EP2322221B1 (en) | 2008-08-05 | 2014-07-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancer |
CA2788718C (en) * | 2010-02-04 | 2019-05-21 | Shinichi Kobayashi | Caprin-1 antibody for treating and/or preventing cancer |
US9796775B2 (en) * | 2011-08-04 | 2017-10-24 | Toray Industries, Inc. | Method for detecting pancreatic cancer |
BR112014002619A2 (pt) * | 2011-08-04 | 2018-10-09 | Toray Industries, Inc | composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica |
KR102005786B1 (ko) | 2012-02-21 | 2019-07-31 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
JP6107655B2 (ja) | 2012-03-30 | 2017-04-05 | 東レ株式会社 | 胆嚢癌の治療及び/又は予防用医薬組成物 |
HUE036424T2 (hu) * | 2012-03-30 | 2018-07-30 | Toray Industries | Gyógyászati készítmény májrák kezelésére és/vagy megelõzésére |
DK2876447T3 (da) | 2012-07-19 | 2020-02-24 | Toray Industries | Fremgangsmåde til detektering af cancer |
AU2013291047B2 (en) | 2012-07-19 | 2018-12-06 | Toray Industries, Inc. | Cancer detection method |
US9862774B2 (en) | 2013-08-09 | 2018-01-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
EP3533466A4 (en) | 2016-10-28 | 2020-06-10 | Toray Industries, Inc. | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND / OR PREVENTION |
KR20200136935A (ko) | 2018-03-30 | 2020-12-08 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
KR20220004634A (ko) | 2019-03-15 | 2022-01-11 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | Her2를 표적으로 하는 면역접합체 |
KR20220034784A (ko) | 2019-06-13 | 2022-03-18 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | 아미노벤즈아제핀 화합물, 면역접합체, 및 이의 용도 |
AU2020359446A1 (en) | 2019-09-30 | 2022-04-21 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
JP7709431B2 (ja) | 2019-10-25 | 2025-07-16 | ボルト バイオセラピューティクス、インコーポレーテッド | チエノアゼピン、イムノコンジュゲート、及びそれらの使用 |
BR112022018161A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer |
WO2021182570A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
JPWO2021182572A1 (en:Method) | 2020-03-12 | 2021-09-16 | ||
BR112022018166A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer |
BR112022018157A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer |
EP4146282A1 (en) | 2020-05-08 | 2023-03-15 | Bolt Biotherapeutics, Inc. | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
WO2022036101A1 (en) | 2020-08-13 | 2022-02-17 | Bolt Biotherapeutics, Inc. | Pyrazoloazepine immunoconjugates, and uses thereof |
JPWO2022270524A1 (en:Method) | 2021-06-23 | 2022-12-29 | ||
EP4360648A1 (en) | 2021-06-23 | 2024-05-01 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
CA3227698A1 (en) | 2021-07-27 | 2023-02-02 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
JPWO2023008462A1 (en:Method) | 2021-07-27 | 2023-02-02 | ||
JPWO2023008461A1 (en:Method) | 2021-07-27 | 2023-02-02 | ||
JPWO2023033129A1 (en:Method) | 2021-09-03 | 2023-03-09 | ||
JP2024539993A (ja) | 2021-10-29 | 2024-10-31 | ボルト バイオセラピューティクス、インコーポレーテッド | システイン変異抗体を含むtlrアゴニスト免疫複合体、及びその使用 |
KR20250031149A (ko) | 2022-06-30 | 2025-03-06 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
WO2024043257A1 (ja) | 2022-08-24 | 2024-02-29 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
EP4578459A1 (en) | 2022-08-24 | 2025-07-02 | Toray Industries, Inc. | Pharmaceutical product for treatment and/or prevention of cancer |
WO2024043252A1 (ja) | 2022-08-24 | 2024-02-29 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
JPWO2024048541A1 (en:Method) | 2022-08-30 | 2024-03-07 | ||
CN119768184A (zh) | 2022-08-30 | 2025-04-04 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
WO2024135809A1 (ja) | 2022-12-23 | 2024-06-27 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2024173387A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
WO2025058000A1 (ja) * | 2023-09-13 | 2025-03-20 | 東レ株式会社 | 癌の治療、予防及び/又は診断用医薬組成物 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
ATE340590T1 (de) | 1994-07-13 | 2006-10-15 | Chugai Pharmaceutical Co Ltd | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
WO2000004149A2 (en) | 1998-07-14 | 2000-01-27 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
EP2363484A3 (en) | 1998-04-03 | 2012-04-25 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody |
US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
AU4185100A (en) | 1999-04-02 | 2000-10-23 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
CA2388822A1 (en) | 1999-10-29 | 2001-05-10 | Human Genome Sciences, Inc. | 27 human secreted proteins |
US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
WO2001072295A2 (en) | 2000-03-29 | 2001-10-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
IL155977A0 (en) | 2000-11-30 | 2003-12-23 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
US20040236091A1 (en) | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
EP1516049A4 (en) | 2001-05-11 | 2006-01-11 | Corixa Corp | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER |
KR100583331B1 (ko) | 2001-05-11 | 2006-05-26 | 기린 비루 가부시키가이샤 | 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체 및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는 비인간 동물 |
US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
EP1575480A4 (en) | 2002-02-22 | 2008-08-06 | Genentech Inc | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM |
US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
EP1572116A4 (en) | 2002-11-26 | 2007-12-12 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
US20050202451A1 (en) | 2003-04-29 | 2005-09-15 | Burczynski Michael E. | Methods and apparatuses for diagnosing AML and MDS |
EP2481814A3 (en) | 2003-06-09 | 2012-10-10 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
WO2005007830A2 (en) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
CA2553826A1 (en) | 2004-01-26 | 2005-12-08 | Debiovision Inc. | Neoplasm-specific polypeptides and their uses |
DK1735348T3 (da) | 2004-03-19 | 2012-07-16 | Imclone Llc | Humant anti-epidermalt vækstfaktorreceptorantistof |
PL1730191T3 (pl) | 2004-03-30 | 2011-12-30 | Glaxo Group Ltd | Immunoglobuliny wiążące hosm |
WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
MX2007008768A (es) | 2005-01-21 | 2007-10-19 | Genentech Inc | Dosificacion fija de anticuerpos her. |
CA2598217A1 (en) | 2005-02-18 | 2006-08-24 | Marsha A. Moses | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
US7510842B2 (en) | 2005-03-11 | 2009-03-31 | Vermilllion, Inc. | Biomarker for ovarian and endometrial cancer: hepcidin |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
US8211634B2 (en) | 2006-02-14 | 2012-07-03 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
WO2008073162A2 (en) | 2006-08-17 | 2008-06-19 | Cell Signaling Technology, Inc. | Lysine acetylation sites |
US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US7615349B2 (en) | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
KR20160125535A (ko) | 2008-03-18 | 2016-10-31 | 제넨테크, 인크. | 항-her2 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법 |
KR20160039295A (ko) * | 2008-08-05 | 2016-04-08 | 도레이 카부시키가이샤 | 암의 검출 방법 |
EP2322221B1 (en) | 2008-08-05 | 2014-07-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancer |
WO2010016525A1 (ja) | 2008-08-05 | 2010-02-11 | 東レ株式会社 | 免疫誘導剤 |
MX2012001741A (es) | 2009-08-19 | 2012-03-21 | Merck Patent Gmbh | Anticuerpos para la deteccion de complejos de integrina en material incrustado en parafina fijado con formalina (ffpe). |
BR112012006388B1 (pt) | 2009-09-22 | 2022-01-04 | Probiogen Ag | Método para produzir uma molécula, e, método para produzir uma proteína |
RU2418587C1 (ru) * | 2010-01-21 | 2011-05-20 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") | Способ лечения злокачественных опухолей головного мозга |
CN102822199B (zh) * | 2010-02-04 | 2014-10-15 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
PL2532365T3 (pl) | 2010-02-04 | 2016-12-30 | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
PT2532366T (pt) | 2010-02-04 | 2016-12-20 | Toray Industries | Composição farmacêutica para o tratamento e/ou prevenção de cancro |
CN102834113B (zh) | 2010-02-04 | 2016-03-02 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
CA2788718C (en) | 2010-02-04 | 2019-05-21 | Shinichi Kobayashi | Caprin-1 antibody for treating and/or preventing cancer |
EP2532367B1 (en) | 2010-02-04 | 2018-08-29 | Toray Industries, Inc. | Pharmaceutical agent for treatment and/or prevention of cancer |
KR101271964B1 (ko) | 2010-07-08 | 2013-06-07 | 강원대학교산학협력단 | 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 |
EA201790882A1 (ru) | 2010-07-26 | 2017-08-31 | Ле Лаборатуар Сервье | Способы и композиции для терапии рака печени |
JP5545105B2 (ja) | 2010-08-04 | 2014-07-09 | 株式会社ジェイテクト | トロイダル型無段変速機のディスクの研磨方法およびトロイダル無段変速機のディスクの研磨装置 |
AU2012290957B2 (en) | 2011-08-04 | 2017-04-20 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
US9796775B2 (en) * | 2011-08-04 | 2017-10-24 | Toray Industries, Inc. | Method for detecting pancreatic cancer |
BR112014002619A2 (pt) | 2011-08-04 | 2018-10-09 | Toray Industries, Inc | composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica |
JP6107655B2 (ja) | 2012-03-30 | 2017-04-05 | 東レ株式会社 | 胆嚢癌の治療及び/又は予防用医薬組成物 |
HUE036424T2 (hu) | 2012-03-30 | 2018-07-30 | Toray Industries | Gyógyászati készítmény májrák kezelésére és/vagy megelõzésére |
-
2013
- 2013-02-21 CA CA2864999A patent/CA2864999C/en active Active
- 2013-02-21 JP JP2013512279A patent/JP6187257B2/ja active Active
- 2013-02-21 MX MX2014009747A patent/MX363136B/es unknown
- 2013-02-21 IN IN1714KON2014 patent/IN2014KN01714A/en unknown
- 2013-02-21 BR BR112014021099-3A patent/BR112014021099A2/pt not_active Application Discontinuation
- 2013-02-21 ES ES13751159T patent/ES2749672T3/es active Active
- 2013-02-21 CN CN201380009166.3A patent/CN104114581B/zh active Active
- 2013-02-21 HU HUE13751159A patent/HUE046788T2/hu unknown
- 2013-02-21 AU AU2013223137A patent/AU2013223137B2/en active Active
- 2013-02-21 RU RU2014138039A patent/RU2639522C2/ru active
- 2013-02-21 KR KR1020147020831A patent/KR102005308B1/ko active Active
- 2013-02-21 PL PL13751159T patent/PL2818481T3/pl unknown
- 2013-02-21 WO PCT/JP2013/054312 patent/WO2013125630A1/ja active Application Filing
- 2013-02-21 US US14/379,868 patent/US9260513B2/en active Active
- 2013-02-21 DK DK13751159.8T patent/DK2818481T3/da active
- 2013-02-21 EP EP13751159.8A patent/EP2818481B1/en active Active
- 2013-02-21 PT PT137511598T patent/PT2818481T/pt unknown
Also Published As
Publication number | Publication date |
---|---|
KR102005308B1 (ko) | 2019-07-30 |
BR112014021099A2 (pt) | 2020-12-01 |
CN104114581A (zh) | 2014-10-22 |
EP2818481A1 (en) | 2014-12-31 |
IN2014KN01714A (en:Method) | 2015-10-23 |
CA2864999A1 (en) | 2013-08-29 |
KR20140130670A (ko) | 2014-11-11 |
PT2818481T (pt) | 2019-10-25 |
WO2013125630A1 (ja) | 2013-08-29 |
US9260513B2 (en) | 2016-02-16 |
US20150044221A1 (en) | 2015-02-12 |
ES2749672T3 (es) | 2020-03-23 |
AU2013223137A1 (en) | 2014-09-11 |
DK2818481T3 (da) | 2019-10-14 |
AU2013223137B2 (en) | 2017-10-19 |
CA2864999C (en) | 2020-06-30 |
JP6187257B2 (ja) | 2017-08-30 |
CN104114581B (zh) | 2018-11-30 |
EP2818481B1 (en) | 2019-08-07 |
EP2818481A4 (en) | 2015-10-07 |
RU2639522C2 (ru) | 2017-12-21 |
MX363136B (es) | 2019-03-12 |
RU2014138039A (ru) | 2016-04-10 |
JPWO2013125630A1 (ja) | 2015-07-30 |
MX2014009747A (es) | 2014-11-14 |
HUE046788T2 (hu) | 2020-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2818481T (pt) | Composição farmacêutica para tratamento e/ou prevenção de cancro | |
HUE036424T2 (hu) | Gyógyászati készítmény májrák kezelésére és/vagy megelõzésére | |
HUE036425T2 (hu) | Gyógyászati készítmény epehólyagrák kezelésére és/vagy megelõzésére | |
PL3031826T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
PL2532365T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
PL2532743T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka | |
PT2740793T (pt) | Composição de fármacos para o tratamento e/ou a prevenção de cancro | |
PL2740795T3 (pl) | Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi | |
PL2740798T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworom | |
PT2740489T (pt) | Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático | |
PL2818483T3 (pl) | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi | |
PL2740796T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu i/lub zapobiegania nowotworowi | |
PL2740794T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub profilaktyki nowotworów | |
HUE044611T2 (hu) | Gyógyászati készítmény rák kezelésére | |
PT2824114T (pt) | Composição farmacêutica para o tratamento do cancro | |
PT2532367T (pt) | Agente farmacêutico para o tratamento e/ou prevenção do cancro | |
PL2532366T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
IL236221A (en) | History of theophyridone and pharmacological preparations containing them for the treatment of diseases | |
IL225471B (en) | Preparations for the prevention and treatment of cancer | |
PL2532680T3 (pl) | Kompozycja medyczna do leczenia raka i/lub zapobiegania | |
IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
IL238126B (en) | Compositions for the treatment and prevention of obesity | |
EP2902027A4 (en) | ACTIVE COMPOSITION FOR THE TREATMENT OF TUMORS AND THE USE THEREOF | |
IL221238A0 (en) | Pharmaceutical compositions and methods for the treatment and prevention of cancer |